Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$267.07+7.79 (+3.00%)
Close on Nov 12, 2026Market cap $16.55BP/E 21.7Yield –
Ascendis Pharma A/S EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Ascendis Pharma A/S's EPS for the twelve months ending Jun 30, 2026 was 11.03 EUR. For fiscal 2025 it was -3.76 EUR. The highest annual figure on record is -1.39 EUR in fiscal 2015.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3.76 EUR | – |
| FY2024 | Dec 31, 2024 | -6.53 EUR | – |
| FY2023 | Dec 31, 2023 | -8.55 EUR | – |
| FY2022 | Dec 31, 2022 | -10.40 EUR | – |
| FY2021 | Dec 31, 2021 | -7.00 EUR | – |
| FY2020 | Dec 31, 2020 | -8.28 EUR | – |
| FY2019 | Dec 31, 2019 | -4.69 EUR | – |
| FY2018 | Dec 31, 2018 | -3.17 EUR | – |
| FY2017 | Dec 31, 2017 | -3.68 EUR | – |
| FY2016 | Dec 31, 2016 | -2.58 EUR | – |
| FY2015 | Dec 31, 2015 | -1.39 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 2.83 EUR | – |
| Q1 FY2026 | Mar 31, 2026 | 9.75 EUR | – |
| Q4 FY2025 | Dec 31, 2025 | -0.55 EUR | – |
| Q3 FY2025 | Sep 30, 2025 | -1.00 EUR | – |
| Q2 FY2025 | Jun 30, 2025 | -0.82 EUR | – |
| Q1 FY2025 | Mar 31, 2025 | -1.58 EUR | – |
| Q4 FY2024 | Dec 31, 2024 | -0.64 EUR | – |
| Q3 FY2024 | Sep 30, 2024 | -1.72 EUR | – |
| Q2 FY2024 | Jun 30, 2024 | -1.91 EUR | – |
| Q1 FY2024 | Mar 31, 2024 | -2.30 EUR | – |
| Q4 FY2023 | Dec 31, 2023 | -1.54 EUR | – |
| Q3 FY2023 | Sep 30, 2023 | -2.88 EUR | – |
| Q2 FY2023 | Jun 30, 2023 | -2.16 EUR | – |
| Q1 FY2023 | Mar 31, 2023 | -1.98 EUR | – |
| Q4 FY2022 | Dec 31, 2022 | -3.71 EUR | – |
| Q3 FY2022 | Sep 30, 2022 | -3.03 EUR | – |
| Q2 FY2022 | Jun 30, 2022 | -1.46 EUR | – |
| Q1 FY2022 | Mar 31, 2022 | -2.21 EUR | – |
| Q4 FY2021 | Dec 31, 2021 | -1.87 EUR | – |
| Q3 FY2021 | Sep 30, 2021 | -1.47 EUR | – |
| Q2 FY2021 | Jun 30, 2021 | -2.50 EUR | – |
| Q1 FY2021 | Mar 31, 2021 | -1.17 EUR | – |
| Q4 FY2020 | Dec 31, 2020 | -2.60 EUR | – |
| Q3 FY2020 | Sep 30, 2020 | -2.31 EUR | – |
| Q2 FY2020 | Jun 30, 2020 | -1.97 EUR | – |
| Q1 FY2020 | Mar 31, 2020 | -1.32 EUR | – |
| Q4 FY2019 | Dec 31, 2019 | -1.68 EUR | – |
| Q3 FY2019 | Sep 30, 2019 | -0.53 EUR | – |
| Q2 FY2019 | Jun 30, 2019 | -1.25 EUR | – |
| Q1 FY2019 | Mar 31, 2019 | -1.24 EUR | – |
| Q3 FY2018 | Sep 30, 2018 | -0.81 EUR | – |
| Q2 FY2018 | Jun 30, 2018 | -0.55 EUR | – |
| Q1 FY2018 | Mar 31, 2018 | -1.07 EUR | – |
| Q3 FY2017 | Sep 30, 2017 | -1.04 EUR | – |
| Q2 FY2017 | Jun 30, 2017 | -0.94 EUR | – |
| Q1 FY2017 | Mar 31, 2017 | -0.78 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?